CTLA4 and cancer: The remarkable success of these mAbs have been highlighted by the FDA approval of α-PD-1, α-PD-L1, and α-CTLA-4 mAbs for a number of cancers, and more recently by the Nobel Prize in physiology and medicine to Tasuku Honjo and James Allison (110).